Aethlon Medical Inc (AEMD)

[Makenlight]

Exosomes & Custom Biomarker Development

Exosome technology allows for biomarker discovery, development and validation in biofluid clinical samples, including plasma, serum, CSF and urine. As opposed to using cell culture models, detecting biomarkers in exosomes allows for direct access to clinically relevant, unmanipulated disease information. Cells throughout the body shed exosomes into fluids as a natural delivery system to other cells. Exosomes carry RNA (full length, stable mRNA as well as miRNA and other non-coding RNAs), as well as proteins and DNA, responsible for commanding disease growth that can be accessed easily and repeatedly from a biofluid for analysis by array, PCR or next-generation sequencing.

Exosomes are remarkably stable; fresh or frozen archival samples can be used with equivalent results. Required sample volumes range from 500µL to 30mL, depending on the biofluid, downstream application and project scope (single biomarker vs. full scale array or sequencing panel). All preservation methods (EDTA, Heparin, etc.) are compatible.

Exosome technology has the potential to allow doctors, researchers and drug developers to take repeated genetic snapshots of disease for diagnostic and therapeutic use without the need for a surgical tissue biopsy.

Exosome Diagnostics partners with diagnostic and pharmaceutical companies to develop custom exosome-based biofluid assays for use via qPCR, sequencing and array instruments for use with frozen archival and prospective clinical samples.